Skip to content

Seres Therapeutics, Inc.

MCRB

CIK 0001609809

← back to feed
Revenue (TTM)
$6.5M
−95.0% YoY Q1 Mar 2026
Net Income (TTM)
$1.12M
+4,088.2% YoY Q1 Mar 2026
EPS Diluted (TTM)
$0.34
Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-1,468.3%
Q1 Mar 2026
Net Margin
17.2%
Q1 Mar 2026
Free Cash Flow (TTM)
−$105.43M
Q1 Mar 2026
Cash
$29.83M
Q1 Mar 2026
Total Debt
$110M
Q1 Mar 2026
Shares Outstanding
9.59M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings